ValuEngine Lowers Bellicum Pharmaceuticals, Inc. (BLCM) to Strong Sell
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Friday.
A number of other research firms have also recently issued reports on BLCM. Wells Fargo & Company restated an “outperform” rating and set a $31.00 target price on shares of Bellicum Pharmaceuticals in a research note on Tuesday, June 27th. Cantor Fitzgerald restated an “overweight” rating and set a $35.00 target price on shares of Bellicum Pharmaceuticals in a research note on Monday, June 26th. Ladenburg Thalmann Financial Services set a $31.00 target price on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, June 24th. Raymond James Financial, Inc. restated a “buy” rating on shares of Bellicum Pharmaceuticals in a research note on Tuesday, June 27th. Finally, Jefferies Group LLC cut their target price on shares of Bellicum Pharmaceuticals from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, May 9th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $26.20.
Bellicum Pharmaceuticals (NASDAQ BLCM) opened at 7.65 on Friday. The firm’s market cap is $253.93 million. The firm’s 50-day moving average is $11.55 and its 200-day moving average is $12.35. Bellicum Pharmaceuticals has a 52-week low of $7.59 and a 52-week high of $23.11.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by $0.09. Bellicum Pharmaceuticals had a negative return on equity of 71.51% and a negative net margin of 17,957.31%. During the same quarter last year, the firm posted ($0.61) EPS. Analysts forecast that Bellicum Pharmaceuticals will post ($2.95) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.dailypolitical.com/2017/08/11/valuengine-lowers-bellicum-pharmaceuticals-inc-blcm-to-strong-sell.html.
In other Bellicum Pharmaceuticals news, VP Ken Moseley sold 13,823 shares of the firm’s stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $12.26, for a total value of $169,469.98. Following the transaction, the vice president now directly owns 14,314 shares of the company’s stock, valued at approximately $175,489.64. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider David M. Spencer sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 10th. The shares were sold at an average price of $11.54, for a total transaction of $115,400.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 30,571 shares of company stock worth $367,295. Insiders own 23.30% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Ronald Blue & Co. LLC purchased a new position in Bellicum Pharmaceuticals during the second quarter valued at approximately $117,000. Clear Harbor Asset Management LLC purchased a new position in Bellicum Pharmaceuticals during the second quarter valued at approximately $118,000. Knott David M purchased a new position in Bellicum Pharmaceuticals during the first quarter valued at approximately $131,000. Eagle Ridge Investment Management purchased a new position in Bellicum Pharmaceuticals during the first quarter valued at approximately $144,000. Finally, American International Group Inc. raised its position in Bellicum Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 852 shares in the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.